ADA Annual Report Highlights Ongoing Diabetes Research

The American Diabetes Association® (ADA) released its 2022 Annual Research Report, which provides background and updates on 200 grants awarded to fund critical research in new treatments and cures for diabetes, precision medicine, and new methods for addressing the health inequities that lead to higher prevalence of diabetes and prediabetes.

“Our research investments are targeted to solve problems critical to people with diabetes. These include reducing unjust health disparities, achieving better outcomes through nutrition and lifestyle, and making precision medicine feasible in a disease that impacts the whole body,” said Robert Gabbay, MD, chief scientific and medical officer for the ADA. “We are also excited to relaunch the impactful Pathway to Stop Diabetes® research program, which invests in the next generation of bold innovators in diabetes.”

The report highlights ongoing research in:

• Beta cell production, which addresses the core cause of diabetes, e.g., the attack of beta cells that are responsible for producing insulin.
• Diabetes management and education programs designed for communities disproportionately impacted by diabetes like Black, Indigenous, and non-white Hispanic populations. 
• The incorporation of trauma-informed mental health services into diabetes management and education programs for under-resourced communities.
• Precision medicine designed to treat diabetes.

In addition, the report provides an update on the Pathway to Stop Diabetes (Pathway) research program. The Pathway program not only supports researchers to explore new methods to drive on diabetes treatment and therapies, but also enhances training opportunities and fosters collaboration for researchers and professionals. 

To learn more about the ADA’s research findings and ongoing areas of study, visit professional.diabetes.org.